Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BHST vs IMMP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMMP Captures Overall Composite Edge (58.4 HOLD vs 58.2 HOLD), While BHST Leads 3–2 on Growth & Valuation Pillars

IMMP Overall Winner 6-Pillar Tally: BHST 3 – 2 IMMP (1 Tie) Matrix Metrics: BHST 2 – 6 IMMP

As of Nov 20, 2026, Immutep Limited (IMMP) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (58.4/100 HOLD vs. 58.2/100 HOLD) after splitting the core matrix 6–2 (led by Valuation Multiples, Growth & Scale), while BHST wins 3–2 across the 6-pillar growth and valuation breakdown. BHST trades at $1.30 (N/M Forward P/E, -18.0% operating margin) versus IMMP at $3.11 (7.1x Forward P/E, -409.3% operating margin).

  • Growth vs. Quality Trade-Off: IMMP earns the overall head-to-head edge with a stronger Unified Composite Score (58.4/100 HOLD vs. BHST 58.2/100 HOLD) and -7.10β · 118% Vol risk profile, whereas BHST leads top-line expansion (+3.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile IMMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BHST vs IMMP
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
TTM Revenue $35M
Forward P/E N/M
Beta / 30D Vol 0.25β · 86% Vol
Unified Composite Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 37
RSI-14: 37.2 · SMA20: $1.55 · SMA50: $1.58
IMMP NASDAQ Head-to-Head Winner
Immutep Limited American Depositary Shares
Pharmaceutical Preparations
$3.11
-9.06% 1D
Market Cap $25.2M
TTM Revenue $20M
Forward P/E 7.1x
Beta / 30D Vol -7.10β · 118% Vol
Unified Composite Score
58.4 / 100 HOLD
Tech 62.0 Fund 38.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.0 · SMA20: $3.27 · SMA50: $2.89

6-Pillar Scorecard Institutional Category Breakdown (BHST 3 – 2 IMMP)

Columns: Metric · BHST · IMMP
1. Valuation Multiples IMMP
Forward P/E N/M 7.1x
Trailing P/E N/M 7.1x
PEG Ratio N/M N/M
EV / Revenue 0.7x 1.3x
2. Growth & Scale IMMP
Revenue Growth (YoY) +3.8% +633.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $35M $20M
Market Cap $29.9M $25.2M
3. Profitability & Quality BHST
Gross Margin 59.0% N/A
Operating Margin -18.0% -409.3%
Net Profit Margin -31.2% 0.0%
Return on Equity (ROE) -142.5% -77.3%
4. Balance Sheet & Cash Flow BHST
Cash Generation (TTM) -$9.4M -$79M EBITDA
Cash Flow Margin -26.6% N/A
Net Cash / Leverage $5.1M Net Cash $5.90 Book/Sh · -77.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat BHST
OpEx & R&D Intensity 77.0% of Rev ($27M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Packaged Foods Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BHST (2) vs IMMP (6)
Institutional Metric BHST IMMP Criterion Row Edge
Market Capitalization
Scale
$29.9M $25.2M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M 7.1x Lower Multiple IMMP
Forward P/E Ratio
Valuation
N/M 7.1x Lower Multiple IMMP
Revenue Growth (YoY)
Growth
+3.8% +633.5% Higher Growth IMMP
Operating Margin (TTM)
Profitability
-18.0% -409.3% Higher Margin BHST
Net Profit Margin
Profitability
-31.2% 0.0% Higher Margin IMMP
Return on Equity (ROE)
Capital Efficiency
-142.5% -77.3% Higher ROE IMMP
52-Week Range Position
Momentum
6% ($1–$7) 56% ($0–$5) Stronger Trend IMMP
Beta / 30D Volatility
Risk Regime
0.25β · 86% Vol -7.10β · 118% Vol Lower Realized Risk BHST
Unified Institutional Score
Composite Signal
58.2 / 100 (HOLD) 58.4 / 100 (HOLD) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$35M $20M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
59.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.7x EV/Rev N/M PEG · 1.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.4M ($5.1M Net Cash) -$79M EBITDA ($5.90 Book/Sh · -77.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IMMP +20.73 pp
BHST: -22.62% · IMMP: -1.89%
3M Horizon IMMP +742.29 pp
BHST: -36.59% · IMMP: +705.7%
6M Horizon IMMP +606.37 pp
BHST: -66.32% · IMMP: +540.05%
1Y Horizon IMMP +161.27 pp
BHST: -79.4% · IMMP: +81.87%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHST vs IMMP. Trailing 12-month operating profitability (BHST -18.0% vs IMMP -409.3%) and valuation multiples (BHST N/M vs IMMP 7.1x Forward P/E) are benchmarked directly in Pillar 4 below.

BHST ADR TTM Benchmark FX-Normalized USD
TTM Revenue$35M
Gross Margin59.0%
Op. Margin-18.0%
ROE / Fwd P/E-142.5% · N/M
IMMP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$20M
Gross MarginN/A
Op. Margin-409.3%
ROE / Fwd P/E-77.3% · 7.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BHST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BHST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IMMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IMMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BHST Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $29.9M market capitalization and -18.0% operating margin.
OpEx & R&D Reinvestment 77.0% of Rev ($27M)
90D Engineering Disclosures 0 Published
IMMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $25.2M market capitalization and -409.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BHST vs IMMP Key Questions & Quantitative Answers

As of Nov 20, 2026, Immutep Limited (IMMP) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (58.4/100 HOLD vs. 58.2/100 HOLD) after splitting the core matrix 6–2 (led by Valuation Multiples, Growth & Scale), while BHST wins 3–2 across the 6-pillar growth and valuation breakdown. BHST trades at $1.30 (N/M Forward P/E, -18.0% operating margin) versus IMMP at $3.11 (7.1x Forward P/E, -409.3% operating margin). Growth vs. Quality Trade-Off: IMMP earns the overall head-to-head edge with a stronger Unified Composite Score (58.4/100 HOLD vs. BHST 58.2/100 HOLD) and -7.10β · 118% Vol risk profile, whereas BHST leads top-line expansion (+3.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile IMMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMMP leads the Growth & Scale pillar: BHST posts +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin), compared with IMMP at +633.5% YoY revenue growth and +0.0% YoY earnings growth on $20M TTM revenue (N/A gross margin, -409.3% operating margin). On trailing 12-month operating scale, BHST generates $35M in USD-normalized revenue versus $20M for IMMP. In operating R&D and SG&A reinvestment, BHST deploys 77.0% of Rev ($27M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMMP.

IMMP screens cheaper on headline valuation multiples. BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin), whereas IMMP trades at 7.1x Forward P/E, 7.1x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHST (-142.5% ROE) versus IMMP (-77.3% ROE) capital efficiency.

In options market volatility and institutional positioning, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk). By comparison, IMMP carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.10β · 118% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.